Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028

Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

Report Code : TIPRE00009653 | Region : Global | Industry : Pharmaceuticals | Published Date : 29/Apr/2022

The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% from 2021 to 2028.

Major factors driving the non-alcoholic steatohepatitis (NASH) market growth include the rising prevalence of NASH and increasing initiatives for the awareness of NASH. The growing number of clinical trials involving combination studies of drugs are likely to introduce future trends in the market during the forecast period. However, the lack of established guidelines for the diagnosis and management of NASH, and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the non-alcoholic steatohepatitis (NASH) market growth.

NASH is a potentially fatal illness that causes extensive scarring and cirrhosis of the liver. NAFLD is the most common chronic liver disease globally. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019. It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20–80% have hyperlipidemia worldwide. NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.

As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020–2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.

Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.

The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market during the forecast period.

The non-alcoholic steatohepatitis (NASH) market, based on application, is segmented into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR during the forecast period.

The non-alcoholic steatohepatitis (NASH) market, based on distribution channel, is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacies segment held the largest share of the market. Moreover, it is expected to register the highest CAGR in the non-alcoholic steatohepatitis (NASH) market during 2021–2028.

The Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), National Healthcare Service (NHS), Centers for Disease Control and Prevention (CDC), Diabetes UK, National Center for Biotechnology Information (NCBI), Korean Diabetes Association (KDA), United Nations (UN) Global Population Prospects, National Statistics Institute, and World Health Organization (WHO) are among the major secondary sources referred to while preparing the report on the non-alcoholic steatohepatitis (NASH) market.

Rising Prevalence of NASH Drives Non-Alcoholic Steatohepatitis (NASH) Market Growth

According to our new research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Application, and Sales Channel,” the market is expected to grow from US$ 1,631.92 million in 2021 to US$ 24,266.81 million by 2028; it is estimated to grow at a CAGR of 47.1% from 2021 to 2028. The report highlights the major factors driving the market, and prominent players and their developments in the market. The growth of the non-alcoholic steatohepatitis (NASH) market is mainly driven by the rising prevalence of NASH and increasing initiatives for the awareness of NASH. However, the lack of established guidelines for the diagnosis and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the market growth.

NASH is a potentially fatal illness that causes extensive scarring and cirrhosis of the liver. NAFLD is the most common chronic liver disease globally. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019. It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20–80% have hyperlipidemia worldwide. NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.

As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020–2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.

Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.

The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market from 2021 to 2028. Further, the selonsertib & cenicriviroc segment is anticipated to register the highest CAGR of 73.3% in the market during the forecast period. Selonsertib is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. It is under investigation in clinical trial NCT03053050—Safety and Efficacy of Selonsertib in Adults with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Cenicriviroc (CVC) is a potent chemokine 2 and 5 receptor antagonist that is currently being developed for the treatment of liver fibrosis in individuals with NASH. Various research studies and clinical trials are being conducted worldwide for selonsertib and CVC, which are expected to drive the market during the forecast period.

Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings are among the leading companies operating in the non-alcoholic steatohepatitis (NASH) market. Product launches, product approvals, mergers and acquisitions, and market initiatives are a few of the major strategies adopted by the companies in this market. For instance, in January 2022, Siemens Healthineers announced the launch of Enhanced Liver Fibrosis (ELF) Test in the US. This is the first time the test was made commercially available in the country, following the de novo marketing authorization from the US Food and Drug Administration (FDA) in August 2021.

Non-Alcoholic Steatohepatitis (NASH) Market, by Region, 2021 (%)

Source: The Insight Partners Analysis

The report segments the non-alcoholic steatohepatitis (NASH) market as follows:

The non-alcoholic steatohepatitis (NASH) market is segmented on the basis of product, application, sales channel, and geography. Based on product, the market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis. Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider. By geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Non-Alcoholic Steatohepatitis Market – By Product

1.3.2 Global Non-Alcoholic Steatohepatitis Market – By Application

1.3.3 Global Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4 Global Non-Alcoholic Steatohepatitis Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East And Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of NASH

5.1.2 Increasing Initiatives for the Awareness of NASH

5.2 Market Restraints

5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3 Market Opportunities

5.3.1 Growing Opportunities in Developing Nations

5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4 Future Trends

5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs

5.5 Impact Analysis

6. Non-alcoholic steatohepatitis (NASH) Market– Global Analysis

6.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

6.1.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

6.1.2 Global Non-Alcoholic Steatohepatitis Market – Market Potential Analysis, By Region

6.2 Market Positioning Analysis of Key Players in Non-Alcoholic Steatohepatitis Market

6.2.1 Company Analysis

6.2.2 Growth Strategy Analysis

6.2.3 Performance of Key Players

6.2.3.1 Intercept Pharmaceuticals, Inc.

6.2.3.2 Galmed Pharmaceuticals, Inc.

7. Global Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1 Overview

7.2 Product Market Revenue and Forecast Analysis (US$ Mn)

7.3 Vitamin E and Pioglitazone

7.3.1 Overview

7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4 Ocaliva

7.4.1 Overview

7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5 Elafibranor

7.5.1 Overview

7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6 Selonsertib & Cenicriviroc

7.6.1 Overview

7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7 Others

7.7.1 Overview

7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)

8. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1 Overview

8.2 Application Market Revenue and Forecast Analysis (US$ Mn)

8.3 Treatment

8.3.1 Overview

8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Diagnosis

8.4.1 Overview

8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1 Overview

9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5 Online Provider

9.5.1 Overview

9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10. Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Geographical Analysis

10.1 North America: Non-Alcoholic Steatohepatitis Market

10.1.1 Overview

10.1.2 North America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3 North America: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.4 North America: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.5 North America: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.6 North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

10.1.6.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.1.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.1.2 US: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.6.1.3 US: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.6.1.4 US: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.6.2 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.2.1 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.2.2 Canada: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.6.2.3 Canada: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.6.2.4 Canada: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.6.3 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.3.1 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.3.2 Mexico: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.6.3.3 Mexico: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.6.3.4 Mexico: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.2 Europe: Non-alcoholic steatohepatitis (NASH) Market

10.2.1 Overview

10.2.2 Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.3 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.4 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.5 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.2.6.1 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.1 Overview

10.2.6.1.2 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.3 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.4 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.5 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.1 Overview

10.2.6.2.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.3 France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.4 France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.5 France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.1 Overview

10.2.6.3.2 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.4 UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.5 UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.1 Overview

10.2.6.4.2 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.3 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.4 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.5 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.1 Overview

10.2.6.5.2 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.3 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.4 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.5 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.1 Overview

10.2.6.6.2 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.3 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.4 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.5 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecasts To 2028

10.3.1 Overview

10.3.2 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market - Revenue and Forecast to 2028 (USD Million)

10.3.3 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.4 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.5 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.3.6.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.1.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.1.2 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.1.3 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.1.4 China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.2.1 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.2.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.2.3 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.2.4 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.3 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.3.1 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.3.2 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.3.3 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.3.4 India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.4.1 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.4.2 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.4.3 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.4.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.5 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.5.1 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.5.2 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.5.3 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.5.4 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.6 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.6.1 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.6.2 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.6.3 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.6.4 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market

10.4.1 Overview

10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.3 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Product (US$ Million)

10.4.4 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Application (US$ Million)

10.4.5 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.4.6 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)

10.4.6.1 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.1.1 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.1.2 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.1.3 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.1.4 UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.4.6.2 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.2.1 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.2.2 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.2.3 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.2.4 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.4.6.3 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.3.1 South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.3.2 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.3.3 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.3.4 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.4.6.4 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.4.1 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.4.2 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.4.3 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.4.4 Rest of Middle East & Africa: D Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.5 South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast To 2028

10.5.1 Overview

10.5.2 South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.3 South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.4 South and Central America: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)

10.5.5 South and Central America: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.5.6 South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

10.5.6.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.2 Brazil: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.6.1.3 Brazil: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)

10.5.6.1.4 Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.5.6.2 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.1 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.2 Argentina: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.6.2.3 Argentina: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)

10.5.6.2.4 Argentina: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.5.6.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.1 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.2 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.6.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)

10.5.6.3.4 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel, 2019–2028 (USD Million)

11. Impact Of COVID-19 Pandemic on Non-alcoholic steatohepatitis (NASH) Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

11.5 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Non-alcoholic steatohepatitis (NASH) Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Non-Alcoholic Steatohepatitis Market

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 Cadila Pharmaceuticals Ltd.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Intercept Pharmaceuticals, Inc

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Novartis AG

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Galmed Pharmaceuticals.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 GENFIT.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 ONE WAY LIVER, S.L

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 BioPredictive S.A.S

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Prometheus Laboratories

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Siemens Healthineers AG

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Laboratory Corporation of America Holdings

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1. Discontinued Drugs and Companies

Table 2. Drug, Phase, and Company

Table 3. North America Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 4. North America Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 5. North America Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 6. US Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 7. US Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 8. US Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 9. Canada: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 10. Canada Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 11. Canada Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 12. Mexico: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 13. Mexico Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 14. Mexico Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 15. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 16. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 17. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 18. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 19. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 20. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 21. France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 22. France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 23. France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 24. UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 25. UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 26. UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 27. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 28. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 29. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 30. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 31. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 32. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 33. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 34. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 35. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 36. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 37. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 38. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 39. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 40. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 41. China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 42. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 43. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 44. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 45. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 46. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 47. India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 48. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 49. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 50. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 51. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 52. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 53. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 54. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 55. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 56. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 57. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Product (US$ Million)

Table 58. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 59. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 60. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 61. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 62. UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 63. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 64. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 65. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 66. South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 67. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 68. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 69. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 70. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 71. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 72. South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 73. South and Central America: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 74. South and Central America: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 75. Brazil: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 76. Brazil: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 77. Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 78. Argentina: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 79. Argentina: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)

Table 80. Argentina: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 81. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 82. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)

Table 83. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 84. Organic Developments Done By Companies

Table 85. Inorganic Developments Done By Companies

Table 86. Glossary of Terms

LIST OF FIGURES.

Figure 1. Non-Alcoholic Steatohepatitis Market Segmentation

Figure 2. Non-Alcoholic Steatohepatitis Market, By Region

Figure 3. Global Non-Alcoholic Steatohepatitis Market Overview

Figure 4. Treatment Segment Held Largest Share of Application Segment in Non-Alcoholic Steatohepatitis Market

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Non-Alcoholic Steatohepatitis Market, by Geography (US$ Million)

Figure 7. Global Non-Alcoholic Steatohepatitis Market - Leading Country Markets (US$ Million)

Figure 8. Global Non-Alcoholic Steatohepatitis Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East And Africa: PEST Analysis

Figure 13. South And Central America: PEST Analysis

Figure 14. Experts Opinion

Figure 15. Non-Alcoholic Steatohepatitis (NASH) Market Impact Analysis of Drivers and Restraints

Figure 16. Global Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis – 2020- 2028

Figure 17. Global Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis – 2021 - 2028

Figure 18. Global Non-Alcoholic Steatohepatitis Market – Market Potential Analysis, By Region

Figure 19. Market Positioning Analysis of Key Players in Global Non-Alcoholic Steatohepatitis Market

Figure 20. Global Non-Alcoholic Steatohepatitis Market – Comparative Company Analysis

Figure 21. Global Non-Alcoholic Steatohepatitis Market – Growth Strategy Analysis

Figure 22. Product Market Analysis and Forecast 2021 and 2028 (%)

Figure 23. Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

Figure 24. Ocaliva Revenue and Forecast to 2028 (US$ Mn)

Figure 25. Elafibranor Revenue and Forecast to 2028 (US$ Mn)

Figure 26. Selonsertib Revenue and Forecast to 2028 (US$ Mn)

Figure 27. Others Revenue and Forecast to 2028 (US$ Mn)

Figure 28. Application Market Analysis and Forecast 2021 and 2028 (%)

Figure 29. Treatment Market Revenue and Forecast to 2028 (US$ Mn)

Figure 30. Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

Figure 31. Sales Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 32. Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 33. Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 34. Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

Figure 35. North America: Non-Alcoholic Steatohepatitis Market, by Key Country – Revenue (2021) (US$ Million)

Figure 36. North America Non-Alcoholic Steatohepatitis Market Revenue and Forecast to 2028 (US$ Million)

Figure 37. North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

Figure 38. US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39. Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40. Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

Figure 41. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (US$ Million)

Figure 42. Europe: Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 43. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

Figure 44. Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 48. Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 49. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 50. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (USD Million)

Figure 51. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (USD Million)

Figure 52. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

Figure 53. China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 54. Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 55. India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028(USD Million)

Figure 56. Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 57. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 58. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

Figure 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 61. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)

Figure 62. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 63. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 64. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 65. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 66. South and Central America: Non-Alcoholic Steatohepatitis Market, by Key Country – Revenue (2021) (USD Million)

Figure 67. South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast to 2028 (USD Million)

Figure 68. South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

Figure 69. Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

Figure 70. Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

Figure 71. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

Figure 72. Impact of COVID-19 Pandemic in North American Country Markets

Figure 73. Impact of COVID-19 Pandemic in European Country Markets

Figure 74. Impact of COVID-19 Pandemic in Asia Pacific Countries

Figure 75. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets

Figure 76. Impact of COVID-19 Pandemic in South and Central America Country Markets

Figure 77. Growth Strategies in the Non-Alcoholic Steatohepatitis Market

List of Companies:

1. Genfit SA

2. One Way Liver, S.L.

3. BioPredictive S.A.S

4. Cadila Pharmaceuticals Ltd.

5. Prometheus Laboratories

6. Siemens Healthineers AG

7. Intercept Pharmaceuticals, Inc.

8. Novartis AG

9. Galmed Pharmaceuticals

10. Laboratory Corporation of America Holdings

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Non-Alcoholic Steatohepatitis market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global Non-Alcoholic Steatohepatitis market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

TOP